Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies.
Linda HarrisThomas O'ConnellJonathan J WoolleyGilbert L'ItalienTamela MartinVladimir CoricJames A MorenPublished in: Advances in therapy (2023)
In consideration of the migraine-specific acute medications used in FFS Medicaid 2020, for patients using CGRP mAbs for prevention, medication costs may vary significantly with the number of breakthrough attacks treated per month and the type of migraine-specific acute therapy used.
Keyphrases
- end stage renal disease
- liver failure
- newly diagnosed
- ejection fraction
- chronic kidney disease
- respiratory failure
- prognostic factors
- healthcare
- health insurance
- intensive care unit
- patient reported outcomes
- mesenchymal stem cells
- hepatitis b virus
- acute respiratory distress syndrome
- mechanical ventilation
- smoking cessation